Grufity logoGrufity logo

Tandem Diabetes Care Inc Stock Research

TNDM

40.61USD+0.68(+1.70%)Market Closed

Market Summary

USD40.61+0.68
Market Closed
1.70%

TNDM Alerts

TNDM Stock Price

TNDM RSI Chart

TNDM Valuation

Market Cap

2.6B

Price/Earnings (Trailing)

-27.7

Price/Sales (Trailing)

3.27

EV/EBITDA

-32.1

Price/Free Cashflow

160.07

TNDM Price/Sales (Trailing)

TNDM Profitability

EBT Margin

-11.59%

Return on Equity

-21.5%

Return on Assets

-8.99%

Free Cashflow Yield

0.62%

TNDM Fundamentals

TNDM Revenue

Revenue (TTM)

801.2M

Revenue Y/Y

5%

Revenue Q/Q

7.8%

TNDM Earnings

Earnings (TTM)

-94.6M

Earnings Y/Y

-246.67%

Earnings Q/Q

67.63%

Price Action

52 Week Range

33.52123.96
(Low)(High)

Last 7 days

-3.7%

Last 30 days

11.4%

Last 90 days

-11.2%

Trailing 12 Months

-65.8%

TNDM Financial Health

Current Ratio

5.14

TNDM Investor Care

Shares Dilution (1Y)

1.07%

Diluted EPS (TTM)

-1.48

Peers (Alternatives to Tandem Diabetes Care)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
108.0B
18.4B
6.78% 4.67%
45.81
5.86
7.84% 18.25%
89.4B
6.2B
9.55% -17.45%
67.62
14.37
8.97% -22.43%
71.6B
12.7B
6.16% 10.96%
102.61
5.65
6.68% -32.95%
70.1B
19.0B
4.93% -5.45%
43.54
3.69
-0.43% -8.78%
50.3B
5.4B
1.40% -30.34%
33.07
9.35
2.86% 1.25%
MID-CAP
7.2T
489.7M
12.57% 9.89%
82.2K
16.8K
106.51% 2464.23%
10.6B
847.1M
6.58% 27.77%
-5.3K
12.54
13.32% -137.89%
5.6B
1.0B
-4.49% -25.70%
32.76
5.52
6.76% 24.45%
3.7B
410.9M
3.48% -19.57%
-32.24
9.11
27.29% -14.60%
2.6B
801.2M
11.35% -65.77%
-27.7
3.27
14.00% -707.69%
SMALL-CAP
1.7B
350.9M
6.62% 37.78%
-10.93
4.74
44.26% -5.42%
1.5B
138.6M
-26.53% -5.16%
-27.28
10.83
36.62% -10.44%
1.4B
820.0M
2.39% -14.54%
27.4
1.69
10.13% 701.59%
833.4M
239.8M
0.76% -10.38%
-22.01
3.47
-4.74% -31.15%

Financials for Tandem Diabetes Care

Income Statement (Last 12 Months)
(In Thousands)
* denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Revenue1.3%801,218790,712765,792737,669702,799
Gross Profit0.4%412,987411,193403,513394,021376,215
Operating Expenses6.8%505,834473,525410,632383,469353,562
  S&GA Expenses8.5%335,681309,488290,307276,216261,508
  R&D Expenses12.2%120,325107,25392,054--
EBITDA-69.8%-76,239-44,90120,81031,914-
EBITDA Margin-67.6%-0.10*-0.06*0.03*0.05*-
Earnings Before Taxes-41.6%-92,852-65,593-12,4444,60615,901
EBT Margin-39.7%-0.12*-0.08*-0.02*0.01*-
Interest Expenses-50.0%4,3138,6284,313--
Net Income-39.2%-94,593-67,933-13,1695,89515,566
Net Income Margin-37.4%-0.12*-0.09*-0.02*0.01*-
Free Cahsflow-45.6%16,36730,06350,87983,175-
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Assets0.5%1,0531,0481,0371,015905
  Current Assets1.9%850834835818812
    Cash Equivalents39.4%17312411594.0071.00
  Inventory6.1%11110588.0080.0069.00
  Net PPE-6.0%69.0073.0059.0050.0050.00
Liabilities-2.1%613626587578472
  Current Liabilities-4.8%165174139132132
Shareholder's Equity4.3%440422450437433
  Retained Earnings-2.2%-729-713-664-649-634
  Additional Paid-In Capital2.7%1,1711,1401,1181,0901,068
Accumulated Depreciation14.2%56.0049.00---
Shares Outstanding0.4%65.0064.0064.0064.0064.00
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q42022Q32022Q22022Q12021Q4
Cashflow From Operations-21.5%50.0064.0074.0096.00111
  Share Based Compensation9.5%85.0078.0071.0066.0061.00
Cashflow From Investing141.8%33.00-79.43-104-175-186
Cashflow From Financing-36.7%17.0027.0046.0052.0052.00

Risks for TNDM

What is the probability of a big loss on TNDM?

100%


Probability that Tandem Diabetes Care stock will be more than 20% underwater in next one year

81.2%


Probability that Tandem Diabetes Care stock will be more than 30% underwater in next one year.

45.8%


Probability that Tandem Diabetes Care stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does TNDM drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Tandem Diabetes Care was unfortunately bought at previous high price.

Drawdowns

Returns for TNDM

Cumulative Returns on TNDM

-10.5%


7-Year Cumulative Returns

51.8%


5-Year Cumulative Returns

-16.3%


3-Year Cumulative Returns

What are the long-term rolling returns for TNDM?

FIve years rolling returns for Tandem Diabetes Care.

Annualized Returns

Which funds bought or sold TNDM recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-03-23
MetLife Investment Management, LLC
reduced
-1.98
-165,593
1,925,880
0.01%
2023-03-17
American Portfolios Advisors
reduced
-48.02
-7,790
5,646
-%
2023-03-10
Financial Alternatives, Inc
new
-
279,724
279,724
0.28%
2023-03-10
BAILLIE GIFFORD & CO
unchanged
-
-763,375
11,825,600
0.01%
2023-03-10
VICTORY CAPITAL MANAGEMENT INC
added
14.62
239,632
3,373,630
-%
2023-03-06
Rockefeller Capital Management L.P.
reduced
-7.93
-8,000
52,000
-%
2023-02-28
Voya Investment Management LLC
reduced
-40.03
-2,556,790
3,298,210
-%
2023-02-24
NATIXIS
reduced
-3.47
-127,750
840,250
-%
2023-02-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
unchanged
-
-28,000
432,000
-%
2023-02-21
NORTHWESTERN MUTUAL INVESTMENT MANAGEMENT COMPANY, LLC
reduced
-35.84
-176,503
267,497
0.01%

1–10 of 43

Latest Funds Activity

Are funds buying TNDM calls or puts?
Calls
Puts
Are funds bullish or bearish(Calls - Puts)?
Net Call Options
No. of funds that own TNDM
No. of Funds

Tandem Diabetes Care News

Simply Wall St

Insiders may be rethinking their US$511k Tandem Diabetes Care, Inc. (NASDAQ:TNDM) investment now that the company has lost US$116m in value.

Simply Wall St,
12 hours ago

InvestorsObserver

Mass Device

Yahoo Finance

Schedule 13G FIlings of Tandem Diabetes Care

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2023
capital world investors
7.7%
4,978,524
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 09, 2023
vanguard group inc
9.53%
6,127,229
SC 13G/A
Jan 24, 2023
blackrock inc.
9.9%
6,345,760
SC 13G
Jul 11, 2022
fmr llc
-
0
SC 13G/A
Feb 11, 2022
capital world investors
5.6%
3,543,503
SC 13G/A
Feb 11, 2022
jackson square partners, llc
3.94%
2,504,346
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G/A
Jan 10, 2022
blackrock inc.
10.2%
6,478,638
SC 13G/A
Feb 16, 2021
capital world investors
5.1%
3,164,366
SC 13G

TNDM Fair Value

Tandem Diabetes Care fair value in different scenarios

The table shows the Fair Value estimates for Tandem Diabetes Care for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
Fair ValueVery PessimisticPessimisticBase CaseOptimisticVery Optimistic
Very Low Inflation

3.24

-92.02%

5.42

-86.65%

11.80

-70.94%

23.94

-41.05%

48.44

19.28%
Current Inflation

3.09

-92.39%

5.03

-87.61%

10.60

-73.90%

21.02

-48.24%

41.96

3.32%
Very High Inflation

2.90

-92.86%

4.56

-88.77%

9.16

-77.44%

17.61

-56.64%

34.45

-15.17%

Historical Tandem Diabetes Care Fair Value Estimates


Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price

Recent SEC filings of Tandem Diabetes Care

View All Filings
Date Filed Form Type Document
Mar 17, 2023
4
Insider Trading
Mar 07, 2023
4
Insider Trading
Mar 01, 2023
4
Insider Trading
Mar 01, 2023
4
Insider Trading
Mar 01, 2023
4
Insider Trading
Mar 01, 2023
4
Insider Trading
Mar 01, 2023
4
Insider Trading
Mar 01, 2023
4
Insider Trading
Mar 01, 2023
4
Insider Trading
Feb 23, 2023
4/A
Insider Trading

Latest Insider Trading transactions for TNDM

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-03-15
Carpenter Rick
acquired
-
-
406
chief technical officer
2023-03-15
Carpenter Rick
sold (taxes)
-5,815
42.14
-138
chief technical officer
2023-03-03
BERGER DAVID B
sold
-411,884
41.1884
-10,000
evp & chief operating officer
2023-03-03
BERGER DAVID B
acquired
188,600
18.86
10,000
evp & chief operating officer
2023-02-27
Leal James
sold (taxes)
-5,201
35.87
-145
svp, operations
2023-02-27
HANSEN BRIAN B
acquired
-
-
407
evp & chief commercial officer
2023-02-27
Sheridan John F
sold (taxes)
-11,048
35.87
-308
president & ceo
2023-02-27
Morrison Susan
acquired
-
-
407
evp & chief admin. officer
2023-02-27
Gasser Elizabeth Anne
sold (taxes)
-5,488
35.87
-153
evp, chief strategy officer
2023-02-27
BERGER DAVID B
sold (taxes)
-5,954
35.87
-166
evp & chief operating officer

1–10 of 50

John F. Sheridan
2000
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

TNDM Income Statement

2022-12-31
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Income Statement [Abstract]   
Sales$ 801,217$ 702,799$ 498,830
Cost of sales388,231326,584238,310
Gross profit412,986376,215260,520
Operating expenses:   
Selling, general and administrative335,681261,508204,903
Research and development139,11492,05463,574
Acquired in-process research and development expenses31,03900
Total operating expenses505,834353,562268,477
Operating income (loss)(92,848)22,653(7,957)
Other income (expense), net:   
Interest income and other, net6,0576741,567
Interest expense(6,208)(6,040)(12,805)
Change in fair value of common stock warrants147(1,386)(17,087)
Total other expense, net(4)(6,752)(28,325)
Income (loss) before income taxes(92,852)15,901(36,282)
Income tax expense (benefit)1,742335(1,900)
Net income (loss)(94,594)15,566(34,382)
Other comprehensive income (loss):   
Unrealized loss on short-term investments(2,233)(693)(20)
Foreign currency translation gains (losses)1,032(143)118
Comprehensive income (loss)$ (95,795)$ 14,730$ (34,284)
Net income (loss) per share - basic (in dollars per share)$ (1.47)$ 0.25$ (0.56)
Net income (loss) per share - diluted (in dollars per share)$ (1.47)$ 0.24$ (0.56)
Weighted average shares used to compute basic net income (loss) per share (in shares)64,14663,00060,990
Weighted average shares used to compute diluted net income (loss) per share (in shares)64,14664,34960,990

TNDM Balance Sheet

2022-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 172,517$ 71,181
Short-term investments444,384552,630
Accounts receivable, net114,717110,725
Inventories111,11768,551
Prepaid and other current assets7,2418,433
Total current assets849,976811,520
Property and equipment, net68,55250,386
Operating lease right-of-use assets110,62627,503
Other long-term assets23,63115,728
Total assets1,052,785905,137
Current liabilities:  
Accounts payable55,73028,032
Accrued expenses9,5959,419
Employee-related liabilities38,68251,556
Operating lease liabilities13,1219,279
Deferred revenue18,83710,182
Other current liabilities29,32523,388
Total current liabilities165,290131,856
Convertible senior notes, net - long-term283,232281,467
Operating lease liabilities - long-term123,52423,922
Deferred revenue - long-term16,87416,940
Other long-term liabilities23,91817,840
Total liabilities612,838472,025
Commitments and contingencies (Note 13)00
Stockholders’ equity:  
Common stock, $0.001 par value; 200,000 shares authorized, 64,513 and 63,833 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively.6564
Additional paid-in capital1,170,8881,068,259
Accumulated other comprehensive loss(1,817)(616)
Accumulated deficit(729,189)(634,595)
Total stockholders’ equity439,947433,112
Total liabilities and stockholders’ equity$ 1,052,785$ 905,137